Aduro BioTech Inc (ADRO) Shares Bought by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. lifted its holdings in shares of Aduro BioTech Inc (NASDAQ:ADRO) by 42.2% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 233,349 shares of the biotechnology company’s stock after buying an additional 69,278 shares during the period. Schwab Charles Investment Management Inc. owned about 0.30% of Aduro BioTech worth $1,634,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of ADRO. Wilbanks Smith & Thomas Asset Management LLC boosted its stake in Aduro BioTech by 150.2% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 83,670 shares of the biotechnology company’s stock worth $586,000 after purchasing an additional 50,230 shares during the period. Bank of New York Mellon Corp boosted its stake in Aduro BioTech by 19.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,247 shares of the biotechnology company’s stock worth $1,541,000 after purchasing an additional 36,387 shares during the period. Rhumbline Advisers boosted its stake in Aduro BioTech by 52.2% during the 2nd quarter. Rhumbline Advisers now owns 60,733 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 20,821 shares during the period. Alps Advisors Inc. boosted its stake in Aduro BioTech by 14.2% during the 2nd quarter. Alps Advisors Inc. now owns 114,257 shares of the biotechnology company’s stock worth $800,000 after purchasing an additional 14,187 shares during the period. Finally, Baillie Gifford & Co. raised its position in Aduro BioTech by 69.6% during the 2nd quarter. Baillie Gifford & Co. now owns 2,810,508 shares of the biotechnology company’s stock worth $19,673,000 after buying an additional 1,153,771 shares during the last quarter. 49.00% of the stock is owned by institutional investors.

Shares of Aduro BioTech stock opened at $6.08 on Friday. The firm has a market cap of $581.09 million, a price-to-earnings ratio of -4.27 and a beta of 2.22. Aduro BioTech Inc has a one year low of $5.10 and a one year high of $10.10.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $2.64 million during the quarter, compared to the consensus estimate of $3.74 million. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. As a group, sell-side analysts expect that Aduro BioTech Inc will post -1.25 earnings per share for the current year.

A number of equities analysts have commented on ADRO shares. Canaccord Genuity restated a “buy” rating and set a $30.00 price objective on shares of Aduro BioTech in a research report on Thursday, August 2nd. HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research report on Tuesday, July 3rd. BidaskClub upgraded shares of Aduro BioTech from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. Finally, William Blair restated a “buy” rating on shares of Aduro BioTech in a research report on Wednesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Aduro BioTech has an average rating of “Hold” and an average target price of $13.33.

In other news, insider Stephen T. Isaacs sold 62,572 shares of the stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $7.91, for a total value of $494,944.52. Following the completion of the transaction, the insider now owns 221,331 shares in the company, valued at approximately $1,750,728.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Elsas Andrea Van sold 10,454 shares of the stock in a transaction dated Tuesday, July 17th. The shares were sold at an average price of $6.96, for a total transaction of $72,759.84. Following the completion of the transaction, the insider now owns 206,215 shares of the company’s stock, valued at approximately $1,435,256.40. The disclosure for this sale can be found here. Insiders sold a total of 123,614 shares of company stock valued at $892,283 in the last quarter. Insiders own 5.00% of the company’s stock.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Further Reading: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply